This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2022 Nov 23;7(1):150.

doi: 10.1038/s41541-022-00578-7.

Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

Emily A Voigt¹, Alana Gerhardt², Derek Hanson³, Madeleine F Jennewein³, Peter Battisti³, Sierra Reed², Jasneet Singh³, Raodoh Mohamath⁴, Julie Bakken³, Samuel Beaver³, Christopher Press², Patrick Soon-Shiong⁵, Christopher J Paddon⁶, Christopher B Fox^{4

7}, Corey Casper^{3

2

4

7

8

9}

Affiliations

Affiliations

¹ RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA. emily.voigt@aahi.org.
² Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
³ RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
⁴ Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
⁵ ImmunityBio, Inc, Culver City, CA, 90232, USA.
⁶ Amyris, Inc, Emeryville, CA, 94608, USA.
⁷ Department of Global Health, University of Washington, Seattle, WA, 98195, USA.
⁸ Department of Medicine, University of Washington, Seattle, WA, 98195, USA.
⁹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.

PMID: 36418864
PMCID: PMC9684560
DOI: 10.1038/s41541-022-00578-7

Published Erratum

Author Correction: A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability

Emily A Voigt et al. NPJ Vaccines. 2022.

. 2022 Nov 23;7(1):150.

doi: 10.1038/s41541-022-00578-7.

Authors

Emily A Voigt¹, Alana Gerhardt², Derek Hanson³, Madeleine F Jennewein³, Peter Battisti³, Sierra Reed², Jasneet Singh³, Raodoh Mohamath⁴, Julie Bakken³, Samuel Beaver³, Christopher Press², Patrick Soon-Shiong⁵, Christopher J Paddon⁶, Christopher B Fox^{4

7}, Corey Casper^{3

2

4

7

8

9}

Affiliations

¹ RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA. emily.voigt@aahi.org.
² Product Development, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
³ RNA Vaccines, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
⁴ Formulation Sciences, Access to Advanced Health Institute (AAHI), Seattle, WA, 98102, USA.
⁵ ImmunityBio, Inc, Culver City, CA, 90232, USA.
⁶ Amyris, Inc, Emeryville, CA, 94608, USA.
⁷ Department of Global Health, University of Washington, Seattle, WA, 98195, USA.
⁸ Department of Medicine, University of Washington, Seattle, WA, 98195, USA.
⁹ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, 98109, USA.

PMID: 36418864
PMCID: PMC9684560
DOI: 10.1038/s41541-022-00578-7

No abstract available

PubMed Disclaimer

Erratum for

A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability.
Voigt EA, Gerhardt A, Hanson D, Jennewein MF, Battisti P, Reed S, Singh J, Mohamath R, Bakken J, Beaver S, Press C, Soon-Shiong P, Paddon CJ, Fox CB, Casper C. Voigt EA, et al. NPJ Vaccines. 2022 Nov 2;7(1):136. doi: 10.1038/s41541-022-00549-y. NPJ Vaccines. 2022. PMID: 36323666 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources